# Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis

Study · id `cardio:ct-nct06785974` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06785974](<https://clinicaltrials.gov/study/NCT06785974>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06785974

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.

## Technical summary

Registry record NCT06785974. Randomized; quadruple masking; primary purpose prevention. Start 2025-02 (anticipated); primary completion 2027-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT06785974, source copy `cardio:ctgov-nct06785974-2025-01-22`, retrieved 2026-10-31)
- Planned start: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06785974, source copy `cardio:ctgov-nct06785974-2025-01-22`, retrieved 2026-10-31)
- Primary completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT06785974, source copy `cardio:ctgov-nct06785974-2025-01-22`, retrieved 2026-10-31)
- Completion: 2030-02 (anticipated) (ClinicalTrials.gov record NCT06785974, source copy `cardio:ctgov-nct06785974-2025-01-22`, retrieved 2026-10-31)
- Countries: Netherlands (ClinicalTrials.gov record NCT06785974, source copy `cardio:ctgov-nct06785974-2025-01-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06785974-2025-01-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis
- Acronym: SPIRAL
- Condition: Atherosclerosis
- Condition: Melanoma
- Condition: Immune-related Adverse Event
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Placebo
- Lead sponsor: Erasmus Medical Center
- Lead sponsor class: OTHER
- Collaborator: Amphia Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Erasmus Medical Center (`cardio:org-erasmus-medical-center`)
- Registry lists this organization as a collaborator: Amphia Hospital (`cardio:org-amphia-hospital`)

## Provenance

Content hash: 3e22759d1155dfa31c8690049526ea9dd9ed16cca27225eeb35411c29ea7cc8e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
